Long-term survival of a patient with scalp angiosarcoma and multiple metastases treated using combination therapy: A case report

被引：11
作者：
Ye, Jun [1 ]
Li, Xiao-Fen [2 ]
Wang, Yong-Dong [1 ]
Yuan, Ying [2 ,3 ]
机构：
[1] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, Hangzhou 310009, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou 310009, Zhejiang, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou 310009, Zhejiang, Peoples R China
来源：
ONCOLOGY LETTERS | 2015年 / 9卷 / 04期
关键词：
angiosarcoma; scalp; comprehensive treatment; CANCER SOFT-TISSUE; BONE SARCOMA GROUP; PROGNOSTIC-FACTORS; PHASE-II; CUTANEOUS ANGIOSARCOMA; LIPOSOMAL DOXORUBICIN; EUROPEAN ORGANIZATION; CHEMOTHERAPY; RADIOTHERAPY; BEVACIZUMAB;
D O I：
10.3892/ol.2015.2919
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Angiosarcoma is a rare and deadly malignancy originating from the vascular endothelial cells. Surgery is the most effective method to cure this disease, but for metastatic angiosarcoma, a chemotherapy-based treatment is the main therapeutic choice. However, there is currently no standard chemotherapy regimen. The current study reports the case of a 66-year-old male with post-operative scalp angiosarcoma recurrence and multiple metastases. The patient obtained a complete response to first-line combination chemotherapy consisting of cyclophosphamide, epirubicin, vincristine and dacarbazine, with a progression-free survival time of eight months. After benefitting from subsequent comprehensive treatment including, cyclophosphamide, epirubicin, vincristine, dacarbazine, docetaxel, cisplatin, gemcitabine and radiotherapy and anti-angiogenic therapy, the patient obtained an overall survival time of 38 months following initial diagnosis.
引用
收藏
页码：1725 / 1728
页数：4
相关论文
共 41 条
[1]   Treatment and outcome of 82 patients with angiosarcoma [J].
Abraham, John A. ;
Hornicek, Francis J. ;
Kaufman, Adam M. ;
Harmon, David C. ;
Springfield, Dempsey S. ;
Raskin, Kevin A. ;
Mankin, Henry J. ;
Kirsch, David G. ;
Rosenberg, Andrew E. ;
Nielsen, G. Petur ;
Desphpande, Vikram ;
Suit, Herman D. ;
DeLancy, Thomas F. ;
Yoon, Sam S. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (06) :1953-1967
[2]   An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas† [J].
Agulnik, M. ;
Yarber, J. L. ;
Okuno, S. H. ;
von Mehren, M. ;
Jovanovic, B. D. ;
Brockstein, B. E. ;
Evens, A. M. ;
Benjamin, R. S. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :257-263
[3]   Angiosarcomas of the head and neck: Clinical and pathologic characteristics [J].
Aust, MR ;
Olsen, KD ;
Lewis, JE ;
Nascimento, AG ;
Meland, NB ;
Foote, RL ;
Suman, VJ .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1997, 106 (11) :943-951
[4]   Management of angiosarcoma. [J].
Budd G.T. .
Current Oncology Reports, 2002, 4 (6) :515-519
[5]  
Cafiero F, 1996, CANCER, V77, P2496, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2496::AID-CNCR12>3.0.CO
[6]  
2-N
[7]  
Calonje E., 2007, Diagnostic histopathology of tumors, V3rd Edit, P41
[8]   Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin [J].
Eiling, S ;
Lischner, S ;
Busch, JO ;
Rothaupt, D ;
Christophers, E ;
Hauschild, A .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (01) :150-153
[9]   Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site:: a retrospective study of 161 cases [J].
Fayette, J. ;
Martin, E. ;
Piperno-Neumann, S. ;
Le Cesne, A. ;
Robert, C. ;
Bonvalot, S. ;
Ranchere, D. ;
Pouillart, P. ;
Coindre, J. M. ;
Blay, J. Y. .
ANNALS OF ONCOLOGY, 2007, 18 (12) :2030-2036
[10]   Angiosarcoma of the small intestine - Possible role for thalidomide? [J].
Fraiman, G ;
Ganti, AK ;
Potti, A ;
Mehdi, S .
MEDICAL ONCOLOGY, 2003, 20 (04) :397-401
12345